566169-97-9
566169-97-9 結(jié)構(gòu)式
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-111514 | 4-(6-Bromo-2-benzothiazolyl)benzenamine | 566169-97-9 | 5 mg | 1440元 |
| 2026/06/05 | HY-111514 | 566169-97-9 4-(6-Bromo-2-benzothiazolyl)benzenamine | 566169-97-9 | 10mg | 2340元 |
| 2024/04/30 | HY-111514 | 566169-97-9 4-(6-Bromo-2-benzothiazolyl)benzenamine | 566169-97-9 | 50mg | 2200元 |
常見問題列表
β-amyloid
4-(6-Bromo-2-benzothiazolyl)benzenamine (compound 6l) plus ultraviolet A (UVA) can induce caspase-3 activity, poly(ADP-ribose)polymerase cleavage, M30 positive CytoDeath staining, and subsequent apoptotic cell death. Treatment of A375 cells with 4-(6-Bromo-2-benzothiazolyl)benzenamine plus UVA results in a decrease in mitochondrial membrane potential (ΔΨ mt ), oxidative phosphorylation system (OXPHOS) subunits, and adenosine triphosphate (ATP) but an increase in mitochondrial DNA 4977-bp deletion via reactive oxygen species (ROS) generation. Transmission electron microscopy (TEM) observations also show major ultrastructural alterations of mitochondria.
4-(6-Bromo-2-benzothiazolyl)benzenamine plus UVA is shown to reduce murine melanoma size in a mouse model. 4-(6-Bromo-2-benzothiazolyl)benzenamine-PDT may serve as a potential ancillary modality for the treatment of melanoma.